Sprouts Farmers Market closes $600 million revolving credit facility
On May 22, 2025, Vigil Neuroscience, Inc., a biotechnology company with a market capitalization of $368 million and currently trading near its 52-week high of $7.95, conducted its 2025 Annual Meeting of Stockholders, where stockholders voted on two key proposals. The company’s stock has shown remarkable momentum, surging over 216% in the past week. The first proposal was the election of two Class I directors to the company’s board, and the second was the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The stockholders approved both proposals. For the election of Class I directors, Gerhard Koenig, Ph.D., received 30,591,045 votes for and 5,131,141 votes withheld, with 6,005,172 broker non-votes. Samantha Budd Haeberlein, Ph.D., received 30,456,675 votes for and 5,265,511 votes withheld, also with 6,005,172 broker non-votes. According to InvestingPro, the company maintains a strong financial position with more cash than debt on its balance sheet, though analysts don’t expect profitability this year.
Regarding the ratification of PricewaterhouseCoopers LLP, the proposal passed with 41,680,781 votes for, 4,275 votes against, and 42,302 abstentions. There were no broker non-votes for this proposal.
No other matters were presented for vote at the Annual Meeting. The information provided is based on the company’s recent SEC filing.
In other recent news, Vigil Neuroscience is set to be acquired by Sanofi (NASDAQ:SNY) for $8 per share, with an additional $2 in contingent value rights, totaling an equity value of approximately $470 million. This acquisition highlights Sanofi’s interest in VG-3927, Vigil’s TREM2 agonist, which is expected to enter Phase II clinical trials for Alzheimer’s disease. Mizuho (NYSE:MFG) Securities, Guggenheim Securities, and William Blair have all downgraded Vigil Neuroscience’s stock rating following the acquisition announcement, reflecting the new valuation under the acquisition terms. Mizuho downgraded the stock to Neutral, citing the non-tradeable contingent value right of $2 per share, which is contingent on VG-3927’s first sales. Guggenheim also adjusted its rating to Neutral and halved the price target to $8.00, aligning with the acquisition offer. Meanwhile, Stifel maintained a Buy rating with an $11.00 price target, viewing the acquisition as a positive outcome for shareholders. JMP analysts downgraded the stock to Market Perform, noting the strategic alignment between Sanofi and Vigil’s VG-3927. The acquisition is anticipated to close in the third quarter of 2025, with no significant regulatory hurdles expected.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.